adaptive biotechnologies corp. - ADPT
ADPT
Close Chg Chg %
15.87 0.18 1.13%
Closed Market
16.05
+0.18 (1.13%)
Volume: 1.06M
Last Updated:
Feb 19, 2026, 4:00 PM EDT
Company Overview: adaptive biotechnologies corp. - ADPT
ADPT Key Data
| Open $15.73 | Day Range 15.57 - 16.18 |
| 52 Week Range 6.26 - 20.74 | Market Cap $2.45B |
| Shares Outstanding 152.67M | Public Float 147.08M |
| Beta 2.18 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.39 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.86M |
ADPT Performance
| 1 Week | 0.06% | ||
| 1 Month | -8.39% | ||
| 3 Months | -13.76% | ||
| 1 Year | 94.07% | ||
| 5 Years | -74.61% |
ADPT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About adaptive biotechnologies corp. - ADPT
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
ADPT At a Glance
Adaptive Biotechnologies Corp.
1165 Eastlake Avenue East
Seattle, Washington 98109
| Phone | 1-206-659-0067 | Revenue | 276.98M | |
| Industry | Biotechnology | Net Income | -59,499,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 54.772% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
ADPT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 8.896 |
| Price to Book Ratio | 11.414 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -62.447 |
| Enterprise Value to Sales | 8.858 |
| Total Debt to Enterprise Value | 0.086 |
ADPT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 5.499 |
| Total Asset Turnover | 0.527 |
ADPT Liquidity
| Current Ratio | 3.339 |
| Quick Ratio | 3.229 |
| Cash Ratio | 2.524 |
ADPT Profitability
| Gross Margin | 73.623 |
| Operating Margin | -20.624 |
| Pretax Margin | -21.466 |
| Net Margin | -21.482 |
| Return on Assets | -11.31 |
| Return on Equity | -28.232 |
| Return on Total Capital | -13.864 |
| Return on Invested Capital | -14.34 |
ADPT Capital Structure
| Total Debt to Total Equity | 96.144 |
| Total Debt to Total Capital | 49.017 |
| Total Debt to Total Assets | 41.026 |
| Long-Term Debt to Equity | 89.945 |
| Long-Term Debt to Total Capital | 45.857 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Adaptive Biotechnologies Corp. - ADPT
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 185.31M | 170.28M | 178.96M | 276.98M | |
Sales Growth
| +20.06% | -8.11% | +5.10% | +54.77% | |
Cost of Goods Sold (COGS) incl D&A
| 78.83M | 97.78M | 82.40M | 73.06M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 28.15M | 22.23M | 19.26M | 17.83M | |
Depreciation
| 26.45M | 20.53M | 17.55M | 16.13M | |
Amortization of Intangibles
| 1.70M | 1.70M | 1.70M | 1.70M | |
COGS Growth
| +24.62% | +24.05% | -15.73% | -11.34% | |
Gross Income
| 106.48M | 72.49M | 96.55M | 203.92M | |
Gross Income Growth
| +16.89% | -31.92% | +33.19% | +111.20% | |
Gross Profit Margin
| +57.46% | +42.57% | +53.95% | +73.62% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 304.64M | 274.10M | 249.89M | 261.04M | |
Research & Development
| 121.83M | 101.58M | 94.33M | 93.77M | |
Other SG&A
| 182.81M | 172.51M | 155.56M | 167.27M | |
SGA Growth
| +1.53% | -10.03% | -8.83% | +4.46% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 2.02M | 25.43M | 9.21M | |
EBIT after Unusual Expense
| (200.19M) | (227.03M) | (162.55M) | (57.12M) | |
Non Operating Income/Expense
| 4.06M | 15.53M | 14.53M | 9.44M | |
Non-Operating Interest Income
| 4.06M | 15.53M | 14.53M | 9.44M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 4.24M | 13.80M | 11.58M | 11.78M | |
Interest Expense Growth
| - | +225.63% | -16.09% | +1.71% | |
Gross Interest Expense
| 4.24M | 13.80M | 11.58M | 11.78M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (200.37M) | (225.30M) | (159.59M) | (59.46M) | |
Pretax Income Growth
| +3.34% | -12.45% | +29.16% | +62.75% | |
Pretax Margin
| -108.13% | -132.32% | -89.18% | -21.47% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (200.37M) | (225.30M) | (159.59M) | (59.54M) | |
Minority Interest Expense
| (177.00K) | (54.00K) | (103.00K) | (42.00K) | |
Net Income
| (200.19M) | (225.25M) | (159.49M) | (59.50M) | |
Net Income Growth
| +3.42% | -12.52% | +29.19% | +62.69% | |
Net Margin Growth
| -108.03% | -132.29% | -89.12% | -21.48% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (200.19M) | (225.25M) | (159.49M) | (59.50M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (200.19M) | (225.25M) | (159.49M) | (59.50M) | |
EPS (Basic)
| -1.4047 | -1.5601 | -1.0842 | -0.3922 | |
EPS (Basic) Growth
| +4.88% | -11.06% | +30.50% | +63.83% | |
Basic Shares Outstanding
| 142.52M | 144.38M | 147.10M | 151.72M | |
EPS (Diluted)
| -1.4047 | -1.5601 | -1.0842 | -0.3922 | |
EPS (Diluted) Growth
| +4.88% | -11.06% | +30.50% | +63.83% | |
Diluted Shares Outstanding
| 142.52M | 144.38M | 147.10M | 151.72M | |
EBITDA
| (170.02M) | (179.38M) | (134.08M) | (39.29M) | |
EBITDA Growth
| +9.56% | -5.50% | +25.25% | +70.70% | |
EBITDA Margin
| -91.75% | -105.34% | -74.93% | -14.19% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 20.857 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.159 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.484 | |
| Last Quarter’s Earnings | -0.09 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.39 | Next Fiscal Year Estimate | -0.266 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 8 | 8 |
| Mean Estimate | -0.16 | -0.13 | -0.48 | -0.27 |
| High Estimates | -0.14 | -0.12 | -0.43 | -0.21 |
| Low Estimate | -0.20 | -0.15 | -0.52 | -0.42 |
| Coefficient of Variance | -11.49 | -7.70 | -5.76 | -24.34 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Adaptive Biotechnologies Corp. - ADPT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Adaptive Biotechnologies Corp. - ADPT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Kyle Piskel Chief Financial Officer | 269,343 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $14.05 per share | 3,784,269.15 |
| Mar 7, 2025 | Chad Robins CEO and Chairman; Director | 2,850,495 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.98 per share | 19,896,455.10 |
| Mar 7, 2025 | Katey Owen Director | 23,726 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Julie Rubinstein President and COO | 607,710 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.98 per share | 4,241,815.80 |
| Mar 7, 2025 | Julie Rubinstein President and COO | 647,754 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Harlan Robins Chief Scientific Officer | 1,279,524 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.99 per share | 8,943,872.76 |
| Mar 7, 2025 | Harlan Robins Chief Scientific Officer | 1,335,577 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.98 per share | 9,322,327.46 |
| Mar 7, 2025 | Harlan Robins Chief Scientific Officer | 1,376,180 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Chad Robins CEO and Chairman; Director | 2,959,249 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.64 per share | 22,608,662.36 |
| Mar 7, 2025 | Chad Robins CEO and Chairman; Director | 3,061,467 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Chad Robins CEO and Chairman; Director | 2,814,350 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.99 per share | 19,672,306.50 |
| Mar 7, 2025 | Robert M. Hershberg Director | 122,690 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Chad Robins CEO and Chairman; Director | 2,931,701 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michael J. Pellini Director | 23,726 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michael J. Pellini Director | 69,690 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michelle Griffin Burris Director | 23,726 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Michelle Griffin Burris Director | 51,685 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.94 per share | 410,378.90 |
| Mar 7, 2025 | Michelle Griffin Burris Director | 67,349 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Peter M. Neupert Director | 23,726 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 7, 2025 | Peter M. Neupert Director | 184,690 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |